Petrelintide: Trials and FDA Status
Petrelintide is a amylin analog. This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.
Where it stands
- US status
- Investigational
- Phase
- Phase 3 (registered, not yet recruiting)
- Sponsor
- Zealand Pharma / Roche
- Expected FDA decision
- None announced
- no primary source states a date (checked 2 Oct 2026)
- Trial IDs (NCT)
- NCT06662539, NCT06926842, NCT07843498, NCT07843485
Reported results
- 2026ZUPREME-1 phase 2 (Lancet Diabetes Endocrinol 2026): weight change at 28 weeks (efficacy estimand)“Mean percentage change in bodyweight from baseline after 28 weeks (efficacy estimand) was -7·9% (95% CI -9·0 to -6·7) with petrelintide 1·0 mg, -7·9% (-9·0 to -6·7) with petrelintide 2·5 mg, -9·8% (-10·9 to -8·6) with petrelintide 5·0 mg, -9·3% (-10·5 to -8·2) with petrelintide 7·0 mg, and -9·4% (-10·5 to -8·3) with petrelintide 9·0 mg versus -1·7% (-2·8 to -0·5) with placebo”pubmed.ncbi.nlm.nih.gov
Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.
Milestones
- NCT07843498 (ZUPREME-3; Phase 3): primary completion (estimated)
- NCT07843485 (ZUPREME-4; Phase 3): primary completion (estimated)
- NCT07843498 (ZUPREME-3; Phase 3): study start (estimated)
- NCT07843485 (ZUPREME-4; Phase 3): study start (estimated)
- NCT07843498 (ZUPREME-3; Phase 3): first posted on ClinicalTrials.gov
- NCT07843485 (ZUPREME-4; Phase 3): first posted on ClinicalTrials.gov
- NCT06926842 (Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2); Phase 2): primary completion
- Published in Diabetes, obesity & metabolism (2026): Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.
- Published in The lancet. Diabetes & endocrinology (2026): Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.
- NCT06662539 (ZUPREME; Phase 2): primary completion
- NCT06926842 (Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2); Phase 2): study start
- NCT06926842 (Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2); Phase 2): first posted on ClinicalTrials.gov
- NCT06662539 (ZUPREME; Phase 2): study start
- NCT06662539 (ZUPREME; Phase 2): first posted on ClinicalTrials.gov
What the petrelintide registry entries specify
ZUPREME-1 (NCT06662539) is titled as a randomised, double-blind, phase 2 dose-finding trial of once-weekly petrelintide against placebo in people with obesity or overweight and weight-related comorbidities.[1]
ZUPREME-1 enrolled 493 participants.[1]
ZUPREME-1 is completed: it started 2024-12-09 and reached primary completion on 2025-09-30.[1]
ZUPREME-2, in type 2 diabetes, enrolled 221 participants.[2]
ZUPREME-2 is also completed: it started 2025-04-22 and reached primary completion on 2026-08-13.[2]
The first phase 3 entry (NCT07843498) lists Hoffmann-La Roche as lead sponsor.[3]
It plans 3900 participants.[3]
It is not yet recruiting: the estimated start is 2026-09-30 and primary completion is estimated for 2028-12-21.[3]
Primary endpoints and trial length
The phase 3 trial's primary outcome is percentage change in body weight from baseline to Week 64.[3]
ZUPREME-1's primary outcome is percent change from baseline in body weight to Week 28.[1]
From start to primary completion, ZUPREME-1 spans 42 weeks, ZUPREME-2 68 weeks and the phase 3 trial an estimated 116 weeks.
Calculated from NCT06662539 start 2024-12-09, primary completion 2025-09-30, type ACTUAL; NCT06926842 start 2025-04-22, primary completion 2026-08-13, type ACTUAL; NCT07843498 start 2026-09-30, primary completion 2028-12-21, type ESTIMATED. Formula: weeks = round((primary completion date - start date) / 7 days)
Published phase 2 result
In ZUPREME-1, efficacy-estimand weight change at 28 weeks was -7.9% at 1.0 mg and -9.8% at 5.0 mg, against -1.7% on placebo.[6]
Common questions
Is petrelintide in phase 3?
A phase 3 trial is registered but not yet recruiting; it plans 3900 participants.[3]
Sources
- 1ZUPREME: Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities (NCT06662539)ClinicalTrials.gov (U.S. National Library of Medicine) · 2024clinicaltrials.govAccessed 2 Oct 2026
- 2Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) (NCT06926842)ClinicalTrials.gov (U.S. National Library of Medicine) · 2025clinicaltrials.govAccessed 2 Oct 2026
- 3ZUPREME-3: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity (NCT07843498)ClinicalTrials.gov (U.S. National Library of Medicine) · 2026clinicaltrials.govAccessed 2 Oct 2026
- 4ZUPREME-4: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (NCT07843485)ClinicalTrials.gov (U.S. National Library of Medicine) · 2026clinicaltrials.govAccessed 2 Oct 2026
- 5Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.Diabetes, obesity & metabolism · 2026PMID 42017294Accessed 2 Oct 2026
- 6Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial.The lancet. Diabetes & endocrinology · 2026PMID 42810355Accessed 2 Oct 2026
Found an error? Report a correction.